Irvine, United States
Afecta Pharmaceuticals, under the slogan "Creating Precision Medicines...More Efficiently", represents a promising venture in the pharmaceutical industry. Specializing in precision medicines, it aims to effectively address chronic disorders and cancers. The company's proprietary Artificial Intelligence platform, PharmetRx®, is used to discover and optimize Multi-Target drug compounds, further formulated through their innovative NanoRx® tissue-specific delivery technology.
An early clinical stage company, Afecta Pharmaceuticals is advancing its lead candidate, AFX-220, which is clinically proven to address disruptive behaviors in children and adolescents with neurodevelopmental disorders like Autism and AD/HD. This focus on a niche and essential health sector, combined with an experienced management team, positions the company favorably for those considering investment opportunities in transformative healthcare solutions.
Based in the United States, Afecta Pharmaceuticals operates within the Health Care, Health and Wellness, and Pharmaceutical industries, although the company has yet to announce specific founding details or recent investments.
